LYELNasdaqPharmaceutical PreparationsUS GAAP · USD

Lyell Immunopharma, Inc.

Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer. Its lead programs, including ronde-cel (LYL314) and LYL273, are designed to improve durability and response rates in hematologic malignancies and solid tumors, while the company also operates its own manufacturing center to control supply and quality.

Kysy yhtiöstä
Liikevaihto0,0milj. USD
−41,0 %v/v
Liikevoitto (EBIT)−269milj. USD
+24,9 %v/v
EBIT-marginaali−748 344,4%
−160 221,5 %-yks.v/v
Nettotulos−274milj. USD
+20,0 %v/v
Vapaa kassavirta−151milj. USD
+7,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−400−300−200−1000100milj. USD2020: 7,8 milj. USD2020: EBIT −212 milj. USD20202021: 11 milj. USD2021: EBIT −215 milj. USD20212022: 85 milj. USD2022: EBIT −187 milj. USD20222023: 0,13 milj. USD2023: EBIT −247 milj. USD20232024: 0,06 milj. USD2024: EBIT −359 milj. USD20242025: 0,04 milj. USD2025: EBIT −269 milj. USD20250,04−269
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Lyell Immunopharma, Inc.

Liiketoiminta

Osuus liikevaihdosta
Clinical CAR T-cell product candidates0 %

Autologous cell therapies in clinical development for hematologic malignancies and solid tumors.

Manufacturing and supply capabilities0 %

Internal cGMP manufacturing for patient-specific CAR T-cell products and viral vectors.

Research and process development0 %

Technology development, translational research and manufacturing process optimization for pipeline assets.

Licensing and strategic collaboration activities0 %

Technology and asset access through acquisitions and license agreements that expand the pipeline.

Asiakkaat

Lyell does not yet sell approved commercial products; its current 'customers' are primarily clinical trial patients, investigators, hospitals and treatment centers participating in its studies. In the future, if approved, its therapies would be used by oncologists and specialty cancer centers treating relapsed/refractory lymphoma and metastatic colorectal cancer. The company also relies on partners, licensors and clinical sites to execute development and manufacturing transitions.

Clinical trial patients

Patients with relapsed/refractory large B-cell lymphoma and advanced mCRC enrolled in trials to test safety and efficacy.

Clinical investigators and trial sites

Hospitals and oncology centers that administer study treatment, monitor outcomes and support enrollment.

Future oncology treatment centers

Specialty centers that would prescribe and infuse approved CAR T products if Lyell reaches commercialization.

Payers and reimbursement stakeholders

Insurers and other payors that will determine access and adoption for premium-priced cell therapies.

Strategia

Lyell’s strategy is to build differentiated CAR T therapies with stronger potency and durability than first-generation products, starting with ronde-cel in large B-cell lymphoma and expanding into solid tumors with LYL273 and other programs. A central priority is to control manufacturing internally through LyFE, which is intended to improve supply reliability, reduce cost and protect proprietary process know-how. The company is also using acquisitions and licensing to broaden its pipeline and accelerate clinical development.

Advance ronde-cel to potential approvalLyhyt aikaväli

It is the lead asset and the main near-term value driver in LBCL.

Transition manufacturing to LyFELyhyt aikaväli

Internal manufacturing is intended to reduce supply risk and improve economics.

Expand into solid tumorsKeskipitkä aikaväli

Solid tumors broaden the addressable market beyond hematologic cancers.

Build a broader next-generation CAR T platformPitkä aikaväli

Platform breadth can improve differentiation and support future partnerships or launches.

Maantiede

Lyell is headquartered and manufactures in the United States, with its LyFE Manufacturing Center in Bothell, Washington and a former West Hills facility that is being closed. The company’s disclosed operations are primarily U.S.-based, but its manufacturing design is intended to meet both U.S. and EU cGMP standards, supporting potential future international development and commercialization. Its LYL273 license excludes mainland China, Hong Kong, Macau and Taiwan, which creates a defined geographic boundary for that asset.

Riskit

Lyell is a pre-revenue clinical-stage company, so its business depends on successful trial outcomes, regulatory approvals and access to capital. Its internal manufacturing strategy reduces some supply-chain risk but also concentrates execution risk in a single facility and in technology transfers for ronde-cel and LYL273. Competition is intense, and approved therapies may be difficult to displace without clearly superior clinical data and reimbursement support.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Manufacturing and supply disruption2Capital needs and dilution3Competitive pressure4Integration and acquisition risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Lead assets are still in trials and may not show sufficient safety or efficacy.

    KohdistuuRonde-celLYL273Other pipeline programs
  2. Manufacturing and supply disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Patient-specific CAR T production is complex and any transfer or quality issue can delay trials.

    KohdistuuLyFE ramp-upWest Hills closureClinical supply continuity
  3. Capital needs and dilutionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company has substantial losses and no commercial revenue to fund operations.

    KohdistuuOngoing R&DManufacturingTrial spend
  4. Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Approved CAR T therapies, bispecifics and other oncology drugs already have physician familiarity and payer coverage.

    Kohdistuu: LBCL and mCRC markets

  5. Integration and acquisition riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    ImmPACT and LYL273 integration may not deliver expected cost savings or pipeline benefits.

    KohdistuuTechnology transferPersonnel retentionUnknown liabilities
Kysy Clarifolta: Lyell Immunopharma, Inc.

Kirjanpito

Harkinnanvaraiset erät
Fair value of SPA put/call instrument

Management accounts for the instrument at fair value through earnings, creating period-to-period volatility.

Vaikutus: Can affect other income/expense and net loss

Acquisition accounting

ImmPACT and LYL273 transactions require valuation of acquired assets, liabilities and contingent obligations.

Vaikutus: Can affect goodwill/intangibles, amortization and future impairment risk

Restructuring and facility closure accounting

West Hills closure and workforce reduction may require severance and exit-related accruals.

Vaikutus: Can affect operating expenses and cash outflows

Clinical and manufacturing asset recoverability

Capitalized facility and equipment values depend on successful development and utilization.

Vaikutus: Potential impairment charges if programs or capacity plans change

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Spyre Therapeutics, Inc.

SYRE · Pharmaceutical Preparations

Allogene Therapeutics, Inc.

ALLO · Biological Products, (No Diagnostic Substances)

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

BriaCell Therapeutics Corp.

BCTXZ · Pharmaceutical Preparations

Cabaletta Bio, Inc.

CABA · Biological Products, (No Diagnostic Substances)

Candel Therapeutics, Inc.

CADL · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026